Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Cardinal Health is a leading provider of healthcare products and services, primarily distributing pharmaceuticals and medical supplies to hospitals, clinics, and retail outlets. Effective July 1, 2008, the company reorganized into three reportable segments: Healthcare Supply Chain Services, Clinical and Medical Products, and All Other.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2008 | Q3 2007 |
|---|---|---|
| Revenue | $24,347.2 | $21,973.4 |
| Gross Margin | $1,364.5 | $1,342.2 |
| Operating Earnings | $426.3 | $489.8 |
| Net Earnings | $249.1 | $301.8 |
| Diluted EPS | $0.69 | $0.82 |
| Cash and Equivalents (End of Period) | $672.2 | $1,289.6 |
| Net Cash Used in Operating Activities | $(352.9) | $408.8 |
| Long-term Obligations (less current) | $3,597.0 | $3,687.4 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11% to $24.3 billion, driven by pharmaceutical price appreciation (8.2% index), increased volume from existing customers, and acquisitions. This was partially offset by a loss of customers ($445 million), largely due to DEA license suspensions and anti-diversion efforts.
- Profitability Decline: Operating earnings decreased 13% to $426 million. While gross margin increased by $22 million, this was outweighed by a $52 million increase in SG&A expenses and a significant $35 million increase in restructuring charges.
- Special Items: Total special items rose to $52.4 million from $22.5 million in the prior year. This includes $49.7 million in restructuring charges related to the reorganization of the segment operating structure.
- Cash Flow: Operating cash flow turned negative, using $353 million compared to providing $409 million in the prior year. This shift was primarily due to a $874 million increase in inventories and a $782 million increase in trade receivables, driven by revenue growth and timing of payments.
Guidance, Outlook, and Risks
- Planned Spin-Off: On September 29, 2008, the company announced a plan to spin off most of its Clinical and Medical Products businesses. Completion is anticipated by mid-2009, subject to regulatory and tax approvals. This may lead to a credit rating review and potential downgrade.
- Management Changes: R. Kerry Clark is expected to retire following the spin-off, with George S. Barrett succeeding him as Chairman and CEO. David L. Schlotterbeck is expected to lead the spin-off entity.
- Regulatory Risks: The company settled with the DEA and seven U.S. Attorneys' Offices regarding license suspensions for controlled substance diversion, agreeing to a $34 million settlement and enhanced compliance programs. Licenses were reinstated in October 2008.
- Tax Contingencies: The IRS has issued Notices of Proposed Adjustments (NPAs) totaling approximately $598 million (excluding penalties/interest) related to tax years 2001-2005. The company disputes these and intends to contest them vigorously.
- Market Conditions: Disruptions in financial markets have limited access to the commercial paper market, though the company maintains adequate liquidity through cash reserves and credit facilities.
Investor Verification Checklist
- Spin-Off Execution: Verify the timeline and regulatory approval status of the Planned Spin-Off of Clinical and Medical Products.
- Working Capital Trends: Monitor the sustainability of the significant increase in inventory and receivables balances and its impact on future operating cash flow.
- IRS Audit Resolution: Track the status of the $598 million proposed tax assessment and the company's legal defense strategy.
- Customer Retention: Assess the long-term impact of the DEA license suspensions on customer loss and revenue recovery in the Healthcare Supply Chain Services segment.
- Restructuring Costs: Confirm the total expected cost of the ongoing restructuring program and the associated headcount reductions.